

AD _____

GRANT NO: DAMD17-94-J-4186


TITLE: The Genetic Analysis of the Role of NEU Differentiation Factor (Heregulin) in NEU-Induced Mammary Carcinomas in the Mouse

PRINCIPAL INVESTIGATOR(S): Archibald S. Perkins, M.D., Ph.D.

CONTRACTING ORGANIZATION: Yale University School of Medicine
New Haven, Connecticut 06520-8047

REPORT DATE: July 13, 1995

TYPE OF REPORT: Annual



PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19950901 047

DTIC QUALITY INSPECTED 5

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2 13 July 1995	3. REPORT TYPE AND DATES COVERED	
			Annual 15 Jul 94 - 14 Jun 95	
4. TITLE AND SUBTITLE			5. FUNDING NUMBERS	
The Genetic Analysis of the Role of Neu Differentiation Factor (Heregulin) in Neu-Induced Mammary Carcinomas in the Mouse			DAMD17-94-J-4186	
6. AUTHOR(S)				
Dr. Archibald Perkins				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)			8. PERFORMING ORGANIZATION REPORT NUMBER	
Yale University School of Medicine New Haven, Connecticut 06520-8047				
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT			12b. DISTRIBUTION CODE	
Approved for public release, distribution unlimited				
13. ABSTRACT (Maximum 200 words)				
<p>Utilization of the mouse to investigate the genetics of mammary carcinoma. Identification of cooperating oncogenes using MMTV-insertion mutagenesis. It is known that over-expression of normal <i>neu</i> in the breast can lead to an increase in mammary carcinomas in transgenic mice, but the tumors occur late, indicating that additional mutations are necessary. One can target these cooperating genes by insertional activation with MMTV. The isolation and characterization of activated genes by molecular cloning techniques may lead to the identification of novel oncogenes involved in murine mammary tumors, and perhaps analogous human tumors as well.</p> <p>Although the ligand heregulin may not bind directly to the p185^{neu} receptor, they have been shown to activate neu kinase activity. Tumorigenesis via p185^{neu} signaling pathways could occur via ligand dependent or ligand independent routes. The relative importance of these two route may be determined genetically. We plan to test for cooperativity between <i>neu</i> and heregulin by creating transgenic mice that overexpress heregulin and cross these to <i>neu</i> transgenics. A dramatic increase in tumor incidence in <i>neu</i> transgenic mice bearing a heregulin transgene would indicate an important role for this ligand in the process.</p>				
14. SUBJECT TERMS			15. NUMBER OF PAGES	
heregulin transgenic mice oncogene cooperation			7	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT	
Unlimited	Unlimited	Unlimited	Unclassified	

GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to *stay within the lines* to meet optical scanning requirements.

Block 1. Agency Use Only (Leave blank).

Block 2. Report Date. Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

Block 3. Type of Report and Dates Covered. State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

Block 4. Title and Subtitle. A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

Block 5. Funding Numbers. To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

C - Contract	PR - Project
G - Grant	TA - Task
PE - Program Element	WU - Work Unit Accession No.

Block 6. Author(s). Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

Block 7. Performing Organization Name(s) and Address(es). Self-explanatory.

Block 8. Performing Organization Report Number. Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es). Self-explanatory.

Block 10. Sponsoring/Monitoring Agency Report Number. (If known)

Block 11. Supplementary Notes. Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in.... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

Block 12a. Distribution/Availability Statement. Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

DOD - See DoDD 5230.24, "Distribution Statements on Technical Documents."

DOE - See authorities.

NASA - See Handbook NHB 2200.2.

NTIS - Leave blank.

Block 12b. Distribution Code.

DOD - Leave blank.

DOE - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.

NASA - Leave blank.

NTIS - Leave blank.

Block 13. Abstract. Include a brief (*Maximum 200 words*) factual summary of the most significant information contained in the report.

Block 14. Subject Terms. Keywords or phrases identifying major subjects in the report.

Block 15. Number of Pages. Enter the total number of pages.

Block 16. Price Code. Enter appropriate price code (*NTIS only*).

Blocks 17. - 19. Security Classifications. Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

Block 20. Limitation of Abstract. This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

ASP In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

ASP In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

ASP In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

ASP In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Accession For	
NRIS GRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By _____	
Distribution/_____	
Availability Codes	
Dist	Avail and/or Special
A-1	

Richard S. Perkins M.D. Ph.D. 7/13/95
PI - Signature Date

TABLE OF CONTENTS

PAGE 1	Front cover
PAGE 2	SF 298
PAGE 3	Foreword
PAGE 4	Table of Contents
PAGE 5	Introduction
PAGE 6	Body
PAGE 6	Conclusions
PAGE 6	References

INTRODUCTION

Like most human cancer, breast cancer is the result of cumulative genetic alterations resulting in loss of growth control. The genes involved in this multistep process have not been elucidated, but include p53, which is altered in more than 50% of cases, the Rb tumor suppressor gene, BRCA1 (5% of cases, mostly inherited, early onset), and the *neu/erbB-2/HER-2* gene in 20-30% of cases (Slamon, Clark, Wong, Levin, Ullrich, & McGuire, 1987); it is this last gene, *neu*, which is the focus of our research. *neu* is a member of a family of genes that encode receptor tyrosine kinases. Other family members include the epidermal growth factor receptor (*EGFR*), *erbB-3*, and *erbB-4*. Activated *neu* oncogenes are potent in transforming cells in culture and transgenic mice overexpressing either mutationally activated or normal *neu* in the mammary gland succumb to adenocarcinomas. The oncogenic effect of both activated and normal *neu* alleles was evident from whole animal studies (Muller, Sinn, Pattengale, Wallace, & Leder, 1988). When normal *c-neu* gene was driven by MMTV in transgenic animals, the tumors were focal adenocarcinomas surrounded by hyperplasia, and were not pregnancy dependent (Guy, Webster, Schaller, Parsons, Cardiff, & Muller, 1992). Since the mode of *c-neu* participation in oncogenesis in humans is amplification rather than activating mutations at *c-neu*, this transgenic model more closely resembles the situation in humans, and the long latency and stochastic nature of the tumors emphasizes the need for other events in carcinogenesis.

The p185^{neu} receptor encoded by *neu* is stimulated by two families of ligands: the EGF family, and the NDF family, which includes heregulin (Holmes, 1992), also known as neu differentiation factor (NDF) (Wen, Peles, Cupples, Suggs, Bacus, Luo, et al., 1992). None of the EGF family members appears to bind directly to p185^{neu}, yet several can activate the receptor via transmodulation. This is believed to occur by binding of the ligand to a high affinity receptor (e.g., EGFR) which then physically associates with p185^{neu} and heterodimerizes. The result of this physical association is phosphorylation and activation of p185^{neu}. Thus a variety of ligands can channel their signal through p185^{neu}, and the partners created depend on what other receptors are expressed in a given cell, and what ligands the cell is exposed to.

NDF is synthesized initially as a transmembrane glycoprotein with a 242 amino acid ectodomain that has an IgG-type motif and an EGF homology domain. The latter, contained in all members of the ErbB-binding ligand family, most likely functions in receptor binding. The transmembrane form, via proteolysis at a site near the ecto-/transmembrane domain junction, is likely to be the precursor for the released form, as is the case for other membrane-bound growth factors.

While little is known about the role of NDF in mammary carcinogenesis, the role of other ligands that act through ErbB family members in malignancy has been investigated. Transgenic mice overexpressing TGF α , either with promoters targeting mammary epithelium, or generalized promoters, display mammary epithelial hyperplasia (Matsui, Halter, Holt, Hogan, & Coffey, 1990) and neoplasia that is often malignant, and often involves the terminal ducts and secretory alveoli. Recent studies show a potent interaction between TGF α and *c-neu* overexpression in transgenic mice: By crossing the MMTV-*c-neu* transgenics with MMTV-TGF α mice, a strong cooperativity was found, resulting in rapid hyperplasia and milk production (Muller, pers. comm). Clearly TGF α has a mitogenic, growth-stimulatory role in breast development and in mammary carcinogenesis. The role of NDFs is unclear, but given the finding that it can promote differentiation and growth cessation in cultured mammary epithelial cells, it may act antagonistically to TGF α . It is the goal of these studies to explore the role of NDFs in mammary carcinogenesis in whole animals using genetic approaches.

BODY

Task 1. Overexpression of NDF: Transgenics *neu* is one of the few genes clearly implicated in the development of human mammary tumors. In addition, TGF α , a ligand for a related growth factor receptor, EGFR, can stimulate p185^{neu} activity via transmodulation, and can also play a stimulatory role in mammary carcinogenesis. We hypothesize that NDF, a putative ligand for p185^{neu} that can stimulate its activity, but which induces the differentiation of mammary cell lines, plays an important role in mammary tumors, especially those in which *neu* also has a causative role. To address this hypothesis, we propose to direct overexpression of NDF to the mammary gland of transgenic mice, and to see what effect this has on mammary growth and development, as well as susceptibility to *c-neu*-induced or MMTV-induced mammary tumors in mice. To this end, we have so far made transgenic mice with NDF under transcriptional control of MMTV (14 founders) and under control of the whey acidic promoter (18 founders). These are being analyzed for expression

Task 2. Targeted deletion of NDF via homologous recombination. In these experiments, we take another approach to testing the same hypothesis that NDF plays an important role in mammary development and neoplasia. If this hypothesis is true, then deletion of the gene encoding NDF should have effects on either mammary gland development or neoplasia, or both. This will be accomplished by targeted deletion of the gene in mice via homologous recombination in embryonic stem (ES) cells. The null allele generated will be made homozygous, and then put onto several genetic backgrounds to assess the effect of this mutation on both normal gland development, and on MMTV-*cneu*-induced mammary carcinomas. We plan to embark on these studies in the coming year.

Task 4. Identification of protooncogenes that can cooperate with *neu*. It is clear from the studies of Muller and coworkers that *neu* does not act alone in the generation of mammary carcinomas in transgenic mice. The long latency (5-8 months) and the solitary, stochastic nature of the tumors argues that other factors are necessary in the disease process. We thus hypothesize that while *neu* is an important oncogene in mammary tumorigenesis, other genes are involved, and we propose to identify what these other genetic factors are by retroviral mutagenesis and proviral tagging. This is being accomplished by infection of transgenic MMTV-*cneu* mice with mouse mammary tumor virus. We expect that infection of transgene with the virus will cause an acceleration of tumorigenesis: a shortening of tumor latency, due to the activation of cellular genes that can cooperate with *cneu* in the development of tumors. The presence of the proviral tag in *cis* to the implicated oncogene will enable us to molecularly clone and characterize them. This approach will allow us to find out what other genes need to be altered, and if the function of these genes can be discerned, what other aspects of cellular growth control must be deregulated, in order to arrive at a fully malignant cell. To perform the experiment correctly, we are backcrossing the MMTV-*cneu* transgene onto the C3H background for five generations, so that the genetic background will be essentially identical to C3H, the high mammary carcinoma strain that carries MMTV. We are almost completed with this phase of the project, and will begin to age mice that have both the transgene and MMTV, to look for acceleration of tumorigenesis.

CONCLUSIONS

The projects are progressing as scheduled, and in the coming year they should begin to yield results.

REFERENCES

- Guy, S., Webster, M., Schaller, M., Parsons, T., Cardiff, R., & Muller, W. (1992). Expression of the *neu* protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci, USA, **89**, 10578-10582.
- Holmes, W. (1992). Science, **256**, 1205-1210.
- Matsui, Y., Halter, S., Holt, J., Hogan, B., & Coffey, R. (1990). Development of mammary hyperplasia and neoplasia in MMTV-TGF α transgenic mice. Cell, **61**, 1147-1155.
- Muller, W., Sinn, E., Pattengale, P., Wallace, R., & Leder, P. (1988). Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated *c-neu* oncogene. Cell, **54**, 105-115.
- Slamon, D., Clark, G., Wong, S., Levin, W., Ullrich, A., & McGuire, R. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/Neu oncogene. Science, **235**, 177-182.

Wen, D., Peles, E., Cupples, R., Suggs, S., Bacus, S., Luo, Y., Levy, R., Koski, R., Lu, H., & Yarden, Y. (1992). Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell, 69, 559-572.